GLP-1 Research Peptides in Australia: Semaglutide, Tirzepatide & Retatrutide Guide

GLP-1 receptor agonists are the most-discussed compound class in metabolic science, and demand from Australian research programs has followed. This guide covers the three compounds that dominate the field and the practical side of sourcing them for in-vitro work.

The class in one paragraph

Glucagon-like peptide-1 is an incretin hormone — released after eating, it signals through the GLP-1 receptor. Native GLP-1 degrades in minutes, so research analogues add structural modifications that extend half-life from minutes to days. Each generation added receptor targets: semaglutide (GLP-1 only), tirzepatide (GLP-1 + GIP), retatrutide (GLP-1 + GIP + glucagon).

Choosing a compound for receptor studies

For single-pathway signalling work, semaglutide remains the reference standard with the deepest literature. Comparative receptor studies typically run tirzepatide alongside it to isolate the contribution of GIP agonism. Retatrutide's triple agonism makes it the frontier compound — phase-2 data associating glucagon-receptor activity with energy-expenditure effects opened an entire research direction.

Sourcing standards for this class

Incretin analogues are long, complex sequences — semaglutide runs 31 amino acids with a fatty-acid side chain — which makes synthesis quality vary sharply between suppliers. Truncated or deletion sequences co-elute close to the target peptide, so demand tight HPLC data (≥99%) and MS identity confirmation on the specific batch. Every vial we ship carries both on its Certificate of Analysis.

Handling notes

All three ship as lyophilised powder. Store at -20°C, reconstitute with bacteriostatic water, and use our reconstitution calculator for concentration math. Reconstituted solutions hold at 2-8°C.

All compounds discussed are for in-vitro laboratory research only. They are not for human or veterinary use, and nothing in this article is medical advice.